nanobiotix

Nanobiotix CEO Dr. Laurent Lévy is elected co-president of the French Technology Platform on Nanomedicine (FTPN)

Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that
its chief executive officer, Laurent Lévy, Ph.D., has been elected as co-president of the French Technolog y Platform
on Nanomedicine (FTPN), effective immediately.
FTPN organizes communication, collaborative work and meetings among the French-based nanomedicine community’s
stakeholders—such as companies, research institutes, universities, hospitals, and patient associations-with representatives
from ministries, regional clusters, government agencies and research foundations.
“I am honored to serve as the co-president of FTPN,” said Dr. Lévy. “FTPN’s mission is to help accelerate the development
of nanomedicine into clinical practice for the benefit of patients. Moving forward, this evolving field of nanomedicine will be
a great challenge, one that our committed board members are ready to undertake.”
FTPN is the counterpart to the European Technology Platform on Nanomedicine (ETPN) and works to ensure
French-based participation in European collaborative projects. Led by market needs and industrial developments,FTPN has
the following goals: (1) identify and represent stakeholders; (2) support industrial RD priorities and initiatives with a strong
link and collaborative work with public-focused research; (3) allow emergence of innovative projects in accordance with
national and local initiatives; (4) inform, and initiate dialogue with, patient associations and the general public; and (5) link
and promote work between regulatory agencies and nanomedicine stakeholders. FTPN’s board of directors includes-copresidents:
Dr. Lévy and Gérard Mathis, CSO, Cis-Bio; Patrice Marche representing INSERM and CNRS and Jean-
Pierre Benoit representing clinical research; Patrick Boisseau, Executive Board member of the European Technology
Platform on Nanomedicine; and, Pierre-Noël Lirsac, French representative to the European Technology Platform
Nanomedicine Mirror Group1.
Nanomedicine2 is the application of nanotechnology to achieve breakthroughs in healthcare. It exploits the improved and
often novel physical, chemical and biological properties of materials at the nanometer scale. Nanomedicine has the potential
to enable early detection and prevention and to essentially improve diagnosis, treatment and follow-up of diseases.
1 Official representative from states member and associated states member from EU.
2 Source: ETPN, Strategic Research Agenda,November 2006.